drugset / Trial / NCT07015905

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905

Phase 3 Recruiting 2000 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Timeline

Start
2025-06-25
Primary completion
2027-02-20
Completion
2027-05-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule
Comparator Enoxaparin sodium Other / unclassified
Subject REGN7508 Monoclonal antibody Intravenous